HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.

AbstractBACKGROUND:
Erlotinib is orally active and selectively inhibits the tyrosine kinase activity of the epidermal growth factor receptor. The pleural space penetration and exposure of erlotinib is poorly understood. Thus, we investigated the pharmacokinetics (PK) of erlotinib and its active metabolite OSI-420 in non-small-cell lung cancer (NSCLC) of malignant pleural effusion (MPE).
PATIENTS AND METHODS:
We analyzed the PK of erlotinib and OSI-420 on days 1 and 8 after beginning erlotinib therapy in 9 patients with MPE. Their concentrations were determined by high-performance liquid chromatography with ultraviolet detection. Blood samples were obtained five times per day: before administration, and 2, 4, 8, and 24 hours after administration. Pleural effusions were obtained once per day, 2 hours after administration on day 1, and before administration on day 8. The exceptions were cases 2 and 4, which had pleural effusions obtained just before drug administration, and 2, 4, 8, and 24 hours after administration.
RESULTS:
The mean percentage of penetration from plasma to pleural effusion for erlotinib was 18% on day 1 and 112% on day 8, while these values for OSI-420 were 9.5% on day 1 and 131% on day 8. The area under the drug concentration-time curve of pleural fluid for erlotinib was 28,406 ng-hr/mL for case 2 and 45,906 ng-hr/mL for case 4.
CONCLUSIONS:
There seems to be a significant accumulation of both erlotinib and OSI-420 in MPE with repeated dosing. Although larger studies will be necessary to determine the true impact of erlotinib MPE accumulation on plasma PK and safety, erlotinib can be administered safely to patients with MPE with respect to efficacy and side effects.
AuthorsKatsuhiro Masago, Yosuke Togashi, Masahide Fukudo, Tomohiro Terada, Kaoru Irisa, Yuichi Sakamori, Young Hak Kim, Tadashi Mio, Ken-Ichi Inui, Michiaki Mishima
JournalClinical lung cancer (Clin Lung Cancer) Vol. 12 Issue 5 Pg. 307-12 (Sep 2011) ISSN: 1938-0690 [Electronic] United States
PMID21775215 (Publication Type: Clinical Trial, Journal Article)
CopyrightCopyright © 2011. Published by Elsevier Inc.
Chemical References
  • OSI-420
  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
Topics
  • Aged
  • Aged, 80 and over
  • Area Under Curve
  • Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
  • Chromatography, High Pressure Liquid
  • Erlotinib Hydrochloride
  • Female
  • Humans
  • Lung Neoplasms (drug therapy, pathology)
  • Male
  • Middle Aged
  • Pleural Effusion (metabolism)
  • Protein Kinase Inhibitors (administration & dosage, pharmacokinetics, therapeutic use)
  • Quinazolines (administration & dosage, pharmacokinetics, therapeutic use)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: